BR112013016905A2 - métodos para diminuir incidência de enterocolite necrosante em bebês, crianças pequenas, ou crianças usando oligossacarídeos do leite humano - Google Patents

métodos para diminuir incidência de enterocolite necrosante em bebês, crianças pequenas, ou crianças usando oligossacarídeos do leite humano

Info

Publication number
BR112013016905A2
BR112013016905A2 BR112013016905A BR112013016905A BR112013016905A2 BR 112013016905 A2 BR112013016905 A2 BR 112013016905A2 BR 112013016905 A BR112013016905 A BR 112013016905A BR 112013016905 A BR112013016905 A BR 112013016905A BR 112013016905 A2 BR112013016905 A2 BR 112013016905A2
Authority
BR
Brazil
Prior art keywords
children
human milk
infants
milk oligosaccharides
methods
Prior art date
Application number
BR112013016905A
Other languages
English (en)
Inventor
O Duska-Mcewen Geralyn
K Linke Hawley
Chow Jomay
Buck Rachael
R Davis Stevem
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR112013016905A2 publication Critical patent/BR112013016905A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pediatric Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)

Abstract

métodos para diminuir incidência de enterocolite necrosante em bebês, crianças pequenas, ou crianças usando oligossacarídeos do leite humano são revelados métodos para redução da incidência de enterocolite necrosante em bebês, crianças pequenas ou crianças usando composições nutricionais incluindo oligossacarídeos do leite humano. as composições nutricionais incluindo os oligossacarídeos do leite humano são eficazes na redução inflamatória e na incidência de doenças inflamatórias.
BR112013016905A 2010-12-31 2011-12-22 métodos para diminuir incidência de enterocolite necrosante em bebês, crianças pequenas, ou crianças usando oligossacarídeos do leite humano BR112013016905A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061428863P 2010-12-31 2010-12-31
US201061428868P 2010-12-31 2010-12-31
PCT/US2011/067018 WO2012092156A1 (en) 2010-12-31 2011-12-22 Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides

Publications (1)

Publication Number Publication Date
BR112013016905A2 true BR112013016905A2 (pt) 2019-09-24

Family

ID=45509697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013016905A BR112013016905A2 (pt) 2010-12-31 2011-12-22 métodos para diminuir incidência de enterocolite necrosante em bebês, crianças pequenas, ou crianças usando oligossacarídeos do leite humano

Country Status (10)

Country Link
US (5) US9539269B2 (pt)
EP (1) EP2658547A1 (pt)
CN (1) CN107019701B (pt)
BR (1) BR112013016905A2 (pt)
CA (1) CA2822219C (pt)
MX (3) MX2013007692A (pt)
MY (2) MY171620A (pt)
NZ (1) NZ611807A (pt)
SG (3) SG191392A1 (pt)
WO (1) WO2012092156A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2875458T3 (es) 2010-12-29 2021-11-10 Abbott Lab Producto nutricional para uso en la reducción de la incidencia de enterocolitis necrosante en un lactante, niño pequeño o niño
WO2012092156A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
BR112013016606A2 (pt) 2010-12-31 2016-09-27 Abbott Lab processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios
ES2657744T3 (es) 2011-07-22 2018-03-06 Abbott Laboratories Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN104507483A (zh) * 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
ES2572831T3 (es) * 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
EP3704957A1 (en) * 2012-09-14 2020-09-09 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
FR2997819B1 (fr) 2012-11-14 2015-06-26 Roquette Freres Utilisation de polysaccharides dans le bien etre intestinal du nourisson et/ou du jeune enfant
MX2015007933A (es) * 2012-12-18 2015-10-09 Abbott Lab Oligosacaridos de leche humana para mejorar sintomas de estres.
WO2014100022A1 (en) * 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
CA2894897C (en) * 2012-12-20 2018-09-18 Abbott Laboratories Nutritional formulations using human milk oligosaccharides for modulating inflammation
EP2996487B1 (en) 2013-03-08 2019-12-11 Axiom Foods Inc. Rice protein supplements
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
US9352020B2 (en) * 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
MX2013003636A (es) * 2013-03-27 2014-09-29 Palsgaard Ind De Mexico S De R L De C V Complemento alimenticio para personas con trisomia 21, transtorno del espectro autista y/o transtorno por deficit de atencion con o sin hiperactividad.
WO2015071403A1 (en) * 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
AU2014350156A1 (en) * 2013-11-15 2016-04-14 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section
EP3071208B1 (en) * 2013-11-15 2021-08-11 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
WO2015077233A1 (en) * 2013-11-19 2015-05-28 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) * 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
EP3673909A1 (en) 2014-04-08 2020-07-01 Abbott Laboratories Nutritional compositions for use in treating enteric infection comprising human milk oligosaccharides
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
EP3197295B1 (en) 2014-09-25 2019-03-06 Nestec S.A. Infant formula system with adaptive levels of human milk oligosaccharides (hmos)
CN115364113A (zh) * 2014-10-29 2022-11-22 格礼卡姆股份公司 合成组合物以及用于治疗肠易激综合症的方法
PL3212198T3 (pl) * 2014-10-29 2021-08-23 Glycom A/S Syntetyczna kompozycja i sposób promowania gojenia się błony śluzowej
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
AU2015340652B9 (en) * 2014-10-31 2020-04-16 Société des Produits Nestlé S.A. Composition comprising Fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition
US20170354696A1 (en) * 2014-11-26 2017-12-14 Abbott Laboratories Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
US10709721B2 (en) 2015-03-05 2020-07-14 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
RU2720201C2 (ru) * 2015-03-05 2020-04-27 Сосьете Де Продюи Нестле С.А. Композиции для применения в профилактике или лечении отита или бронхита у младенцев или детей младшего возраста
EP3265099B1 (en) * 2015-03-05 2023-08-09 Glycom A/S Human milk oligosaccharides for treating acute respiratory tract infections
WO2016139330A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in improving stool consistency or frequency in infants or young children
RU2724590C2 (ru) 2015-08-04 2020-06-25 Сосьете Де Продюи Нестле С.А. Питательные композиции с 2fl и lnnt для применения при индукции кишечной микробиоты, которая похожа на кишечную микробиоту младенцев на грудном вскармливании
EP3458073B1 (en) * 2016-05-19 2023-10-25 Glycom A/S Use of human milk oligosaccharides for treating migraine in patients with inflammatory bowel syndrome
MX2018015725A (es) * 2016-07-01 2019-09-09 Evolve Biosystems Inc Método para facilitar la maduración del sistema inmunitario de mamíferos.
US20190160082A1 (en) * 2016-08-04 2019-05-30 Nestec S.A. Nutritional compositions with 2fl and lnnt for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis
US20180064739A1 (en) * 2016-09-06 2018-03-08 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
WO2018067923A1 (en) * 2016-10-06 2018-04-12 Tallgrass Therapeutics, Llc Compositions and methods for the prevention and treatment of colitis in infants
CN110868870A (zh) 2017-05-12 2020-03-06 艾斯姆食品公司 大米产物及制备它们的系统和方法
US11541068B2 (en) * 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
US11541067B2 (en) * 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing detrimental proteolytic metabolites
EP3641566A1 (en) 2017-06-21 2020-04-29 Abbott Laboratories Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
WO2019008104A1 (en) * 2017-07-07 2019-01-10 Nestec S.A. FORTIFYING HUMAN MILK
US20200281245A1 (en) * 2017-07-07 2020-09-10 Societe Des Products Nestle S.A Human milk fortifier
CN107467677A (zh) * 2017-08-22 2017-12-15 北京特食生物科技研究中心（有限合伙） 一种润肠通便、维持肠道健康的复合营养品及其制备方法与应用
CA3078305A1 (en) * 2017-10-04 2019-04-11 Asian Institute Of Public Health A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections
BR112020010863A2 (pt) 2017-11-30 2020-11-10 Glycom A/S mistura de hmos para tratamento da sensibilidade ao trigo
BR112020008724A2 (pt) * 2017-12-21 2020-11-03 Société des Produits Nestlé S.A. composições para uso na promoção do crescimento e desenvolvimento do músculo intestinal e motilidade intestinal associada
GB2573539A (en) * 2018-05-09 2019-11-13 Mjn Us Holdings Llc Wellbeing supplement for postpartum maternal nutrition
CN111248289B (zh) * 2018-11-30 2023-04-07 内蒙古伊利实业集团股份有限公司 一种组合物、其制备方法及用途
WO2020159357A1 (en) 2019-02-01 2020-08-06 N.V. Nutricia Native whey protein for treating and/or preventing intestinal infection
WO2020168439A1 (en) 2019-02-22 2020-08-27 Aquero Canada Ltd. Fortified milk compositions and their processes of preparation
US12005083B1 (en) 2019-06-24 2024-06-11 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物
US20240307338A1 (en) * 2021-01-27 2024-09-19 Sichuan Jiuzhang Biological Science And Technology Co., Ltd. Use of pharmaceutical composition containing chlorogenic acid in preparation of medicament for treating pathologic jaundice
CN113273695B (zh) * 2021-06-03 2022-05-17 海普诺凯营养品有限公司 一种改善新生儿溶血性高胆红素血症的组合物

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762822A (en) 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
US5260280A (en) 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
JPH03266255A (ja) 1990-03-15 1991-11-27 Canon Inc オートチェンジャ
US5013569A (en) * 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
SE468536B (sv) 1991-07-03 1993-02-01 Bolin Mauritz Ingf Ab Stickkontakt
EP0727216B1 (en) 1994-07-15 2003-05-28 TAIYO KAGAKU Co., LTD. Medicinal composition containing sialic acid derivative
JPH08266255A (ja) 1995-03-30 1996-10-15 Taiyo Kagaku Co Ltd 学習能力向上組成物
WO1997048388A1 (en) 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
JP3552856B2 (ja) 1996-09-27 2004-08-11 雪印乳業株式会社 栄養強化組成物
DE19701382A1 (de) 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
IL131126A (en) 1997-02-21 2003-04-10 Abbott Lab Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof
US6080787A (en) 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
SA98190002B1 (ar) 1997-03-28 2006-06-20 ذي يونيفيرسيتي اوف تننيسي ريسيرش كوربوريشن استخدام أحماض دهنية تحتوي على عدة روابط غير مشبعة polyunsaturated fatty acids لتقليل حدوث الالتهاب المعوي القولوني الناخر incidence of necrotizing enterocolitis
US5906982A (en) 1997-03-31 1999-05-25 Abbott Laboratories Nutritional formulations containing Lacto-N-neoTetraose
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
JPH10327804A (ja) 1997-06-04 1998-12-15 Meiji Milk Prod Co Ltd 核酸関連物質、ｄｈａ、アラキドン酸及び コレステロール含有栄養組成物
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6294206B1 (en) 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
US6497908B1 (en) 1999-07-19 2002-12-24 Seiri Oshiro Turmeric-containing cooking oils and fats
DE19958985A1 (de) 1999-12-07 2001-06-13 Nutricia Nv Oligosaccharidmischung
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
DE60127533D1 (de) 2000-02-17 2007-05-10 Wyeth Corp Prebiotische substanzen enthaltende ernährungszusammensetzungen
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
US7090862B2 (en) 2001-03-30 2006-08-15 Abbott Laboratories Method of improving the antioxidant status of an infant
WO2003003981A2 (en) 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
DE10147100A1 (de) 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
DE10204000A1 (de) 2002-02-01 2003-08-14 Nutricia Nv Sialysierte Kohlenhydrate
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
AR039170A1 (es) 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
OA13142A (en) 2002-10-11 2006-12-13 Wyeth Corp Nutritional formulations containing synbiotic substances.
FI20021989A0 (fi) 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
CN100536836C (zh) 2002-11-26 2009-09-09 芝加哥大学 预防和治疗微生物介导的上皮紊乱的物质和方法
GB0229015D0 (en) 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US7951410B2 (en) 2003-04-14 2011-05-31 Mead Johnson Nutrition Company Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
PL1638416T3 (pl) 2003-06-23 2013-09-30 Nestec Sa Zastosowanie żywnościowego preparatu do optymalizowania działania bariery jelitowej
WO2005000040A1 (en) 2003-06-24 2005-01-06 University Of Kansas Medical Center Infant formula
WO2005055944A2 (en) * 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
US20060039954A1 (en) 2003-12-23 2006-02-23 Gierhart Dennis L Ocular formulations with neuroprotectants to reduce Alzheimer and neurotoxic risks created by large zinc dosages
US7416752B2 (en) 2004-01-06 2008-08-26 Sharp Ingrained Functional Foods, Inc. Method of fortifying seeds with an essential fatty acid, fortified seed and food product
ES1056525Y (es) 2004-01-13 2004-07-16 Perez Alfredo Pineiro Halador de tres rodillos para redes y aparejos de pesca.
US7851451B2 (en) 2004-03-12 2010-12-14 Mti Meta Tech Inc. Formulations for mediating inflammatory bowel disorders
US7090879B2 (en) 2004-03-18 2006-08-15 Abbott Laboratories Nutritional formula containing select carotenoid combinations
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
MXPA06015071A (es) 2004-06-22 2007-08-06 Nutricia Nv Mejoramiento de la integridad de barrera con acidos grasos en pacientes con vih.
EP1721611A1 (en) 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
FR2872047B1 (fr) 2004-06-23 2007-06-15 Oreal Composition pour peaux sensibles associant cation mineral et probiotique(s)
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
JP2008535861A (ja) 2005-04-08 2008-09-04 ザ プロクター アンド ギャンブル カンパニー ヒトの美しさの利益のための経口投与されたプロバイオティクビフィズス菌の使用方法
US20060270739A1 (en) 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
US20060247153A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
US20060246146A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of increasing the salivary sialic acid content in a mammal
US9179702B2 (en) 2005-07-13 2015-11-10 Abbott Laboratories Liquid nutritional compositions containing unsaturated fatty acids
CN1933390B (zh) 2005-09-15 2014-08-13 三星电子株式会社 在正交频分多址通信系统中生成帧的方法
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
EA017195B1 (ru) 2005-11-04 2012-10-30 Арла Фудз Амба Концентрат, полученный из молочного продукта, обогащенный природно встречающейся сиалиллактозой, и способ его получения
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
CA2636724A1 (en) 2006-01-09 2007-08-02 Children's Hospital Medical Center Adiponectin for treatment of various disorders
US20070173438A1 (en) 2006-01-13 2007-07-26 The Scripps Research Institute [PSI[CH2NH]PG4] glycopeptide antibiotic analogs
EP3398606B1 (en) 2006-01-19 2021-09-15 Algenist Holdings, Inc, Microalgae-derived compositions for improving the health and appearance of skin
RU2448720C2 (ru) 2006-03-07 2012-04-27 Нестек С.А. Синбиотическая смесь
PL1993577T3 (pl) 2006-03-10 2014-07-31 Nutricia Nv Stosowanie nieulegających trawieniu sacharydów dla zapewnienia niemowlęciu najlepszego startu po narodzinach
BRPI0708977A2 (pt) 2006-03-23 2011-06-21 Nutricia Nv uso de uma composição, e, composição
JP5118125B2 (ja) 2006-03-23 2013-01-16 ネステク ソシエテ アノニム 高カロリーの栄養補助食品
US20070255598A1 (en) 2006-03-29 2007-11-01 Mccarthy Nancy J Compliance aid, kits comprising the compliance aid, and methods of use
WO2007114683A1 (en) 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
CA2655665A1 (en) 2006-05-26 2007-12-06 Nestec S.A. Methods of use and nutritional compositions of touchi extract
US20080003329A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US8691213B2 (en) 2006-08-04 2014-04-08 SHS International Protein free formula
EP1887017A1 (en) 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
WO2008033520A2 (en) 2006-09-15 2008-03-20 The Regents Of The University Of California Bifidobacterial gene sequences and their use
US20080089981A1 (en) 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
CN101668437A (zh) 2007-03-13 2010-03-10 N.V.努特里奇亚 使用含有非消化性糖的组合物改善能力的方法
NL1033698C2 (nl) 2007-04-16 2008-10-20 Friesland Brands Bv Functioneel serumeiwitproduct voor toepassing in kindervoeding en therapeutische samenstellingen, en werkwijzen ter bereiding daarvan.
JP2010524844A (ja) 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 認知症のためのシンナミド化合物
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
WO2009033011A1 (en) 2007-09-07 2009-03-12 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
JP2009075285A (ja) 2007-09-20 2009-04-09 Fujifilm Corp 半導体デバイスの剥離液、及び、剥離方法
US10251899B2 (en) 2007-10-08 2019-04-09 Mead Johnson Nutrition Company Method for improving stool characteristics in infants
US20090118229A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
PT2217246E (pt) 2007-11-08 2015-02-10 Nestec Sa Utilização de oligossacáridos contendo n-acetil-lactosamina para maturação de respostas imunes em recém-nascidos
WO2009067000A1 (en) 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
WO2009102193A1 (en) 2008-02-12 2009-08-20 N.V. Nutricia A composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants
NL2001377C2 (nl) * 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
PT2266582E (pt) 2008-03-18 2015-09-04 Aleksander Vladimirovich Dikovskiy Composição farmacêutica para a prevenção da disbiose associada à administração enteral de antibióticos
EP2127661A1 (en) 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
GB0809921D0 (en) 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
WO2010023178A1 (en) 2008-08-28 2010-03-04 Chr. Hansen A/S Pharmaceuticals comprising a bacterial polysaccharide
ES2527959T3 (es) 2008-12-02 2015-02-02 Prolacta Bioscience, Inc. Composiciones de permeado de leche humana y métodos para realizarlas y usarlas
CN102257128A (zh) 2008-12-19 2011-11-23 詹内怀恩生物技术股份有限公司 岩藻糖化化合物的合成
US8425955B2 (en) 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
JP2012520325A (ja) 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プレバイオティックオリゴ糖
US9012625B2 (en) 2009-04-07 2015-04-21 Glycom A/S Method for the synthesis of a trisaccharide
CA2761444C (en) 2009-05-11 2018-04-24 Nestec S.A. Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders
TWI381845B (zh) 2009-05-21 2013-01-11 Univ Nat Taiwan 預防和治療幽門螺旋桿菌感染的組成物
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
EP2813230A1 (en) 2009-07-15 2014-12-17 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing infections
US9259447B2 (en) 2009-07-30 2016-02-16 Dupont Nutrition Biosciences Aps Lactic acid bacteria and bifidobacteria for treating endotoxemia
US20110027412A1 (en) 2009-07-31 2011-02-03 Kris Eugene Spence Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
MX2012001362A (es) 2009-07-31 2012-02-22 Nestec Sa Composicion nutricional para lactantes o mascotas alimentados con leche maternal con probioticos y nutrientes seleccionados.
WO2011024468A1 (ja) 2009-08-27 2011-03-03 興和株式会社 新規なスルホンアミド誘導体及びこれを含有する医薬
BR112012017978A2 (pt) 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
EP2563165A1 (en) 2010-04-27 2013-03-06 N.V. Nutricia Use of 6'-sialyl lactose in infant and toddler nutrition
WO2011136636A1 (en) 2010-04-27 2011-11-03 N.V. Nutricia Use of 6'-sialyl lactose in infant nutrition
ES2680920T3 (es) 2010-07-12 2018-09-11 The Regents Of The University Of California Oligosacáridos de leche bovina
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465508A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2465507A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
EP2455387A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
BR112013016606A2 (pt) 2010-12-31 2016-09-27 Abbott Lab processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios
SG191799A1 (en) 2010-12-31 2013-08-30 Abbott Lab Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
WO2012092156A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
CN103763940B (zh) 2010-12-31 2015-10-14 雅培制药有限公司 促进有益微生物群生长的益生菌和人乳寡糖的合益素组合
EP2658546B1 (en) 2010-12-31 2018-12-05 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
BR112013015951A2 (pt) 2010-12-31 2018-07-10 Abbott Lab composições nutricionais compreendendo oligossacarídeos e nucleotídeos de leite humano e usos destas para tratar e/ou prevenir infecção viral entérica.
SG10201707519PA (en) 2010-12-31 2017-10-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
NZ612105A (en) 2010-12-31 2015-02-27 Abbott Lab Human milk oligosaccharides for modulating inflammation
US9567361B2 (en) 2011-05-13 2017-02-14 Glycosyn LLC Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
US20130012472A1 (en) 2011-07-05 2013-01-10 Boston College Composition and methods of inhibiting gastrointestinal pathogen infection
ES2657744T3 (es) 2011-07-22 2018-03-06 Abbott Laboratories Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US20140286908A1 (en) 2011-10-18 2014-09-25 Nestec S.A. Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
US9896470B2 (en) 2012-06-14 2018-02-20 Glycom A/S Enhancing the stability and purity and increasing the bioavailability of human milk oligosaccharides or precursors or blends thereof
SG10202002010VA (en) 2015-03-13 2020-05-28 Evolve Biosystems Inc Compositions that metabolize or sequester free sugar monomers and uses thereof
US10314867B2 (en) 2015-04-23 2019-06-11 Compagnie Gervais Danone Composition for reducing intestinal gas production
RU2758856C2 (ru) 2015-08-04 2021-11-02 Сосьете Де Продюи Нестле С.А. Питательные композиции и детские смеси, включающие bifidobacterium animalis подвида lactis и необязательно смесь олигосахаридов, для индукции кишечной микробиоты, которая похожа на микробиоту младенцев, находящихся на грудном вскармливании
AU2016341734A1 (en) 2015-10-19 2018-05-10 Meiji Co., Ltd. Antiallergic agent for infants
CN108367034A (zh) 2015-10-19 2018-08-03 株式会社明治 面向婴儿的感染防御剂
CA3017357A1 (en) 2016-03-11 2017-09-14 Evolve Biosystems, Inc. A transient commensal microorganism for improving gut health
EP3426269A4 (en) 2016-03-11 2019-10-16 Evolve Biosystems Inc. FOOD COMPOSITIONS FOR DEHUMIDIFICATION
EP3443969B1 (en) 2016-04-13 2021-12-22 Meiji Co., Ltd. Use of bifidobacteria for improving developmental quotient in neonates
GB201611486D0 (en) 2016-06-30 2016-08-17 Promovita Ingredients Ltd Composition for treatment and/or nutrition of poultry
MX2018015725A (es) 2016-07-01 2019-09-09 Evolve Biosystems Inc Método para facilitar la maduración del sistema inmunitario de mamíferos.
WO2018067002A1 (en) 2016-10-05 2018-04-12 N.V. Nutricia Normalization of the intestinal microbiota composition in infants or toddlers fed with an amino acid-based nutritional composition
WO2018106844A1 (en) 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
CN110461345A (zh) 2016-12-15 2019-11-15 加利福尼亚大学董事会 用于调控免疫应答的包含乳酸细菌的口服组合物和与其相关的方法
US20180200312A1 (en) 2017-01-17 2018-07-19 The Regents Of The University Of California Methods and Compositions for Enhancing Memory and/or Reducing Fear and/or Pain of a Host by Administering a Probiotic
KR102089836B1 (ko) 2017-03-15 2020-03-16 (주)바이오일레븐 트립토판분해효소 음성균과 인터페론 감마 형성을 유도하는 균주를 이용한 염증성 질환 예방 및 치료용 약학적 조성물 또는 이를 이용한 치료방법
JP2018177703A (ja) 2017-04-14 2018-11-15 株式会社明治 Ｔｏｌｌ様受容体２活性化用組成物
WO2019000098A1 (en) 2017-06-30 2019-01-03 Wilfrid Laurier University THERMOSIPHON FILLED WITH LIQUID TO A FORCED CIRCULATION PHASE
EP3681521A4 (en) 2017-09-13 2021-05-19 Evolve Biosystems Inc. METABOLOMIC REVIEW OF MAMMAL INFANTS

Also Published As

Publication number Publication date
US10471081B2 (en) 2019-11-12
MX2013007692A (es) 2013-08-15
US9539269B2 (en) 2017-01-10
US11690859B2 (en) 2023-07-04
NZ611807A (en) 2015-02-27
US20170224714A1 (en) 2017-08-10
MY197622A (en) 2023-06-28
CN103338775A (zh) 2013-10-02
WO2012092156A1 (en) 2012-07-05
CA2822219C (en) 2020-12-29
US20230338404A1 (en) 2023-10-26
US11179406B2 (en) 2021-11-23
EP2658547A1 (en) 2013-11-06
US20200078385A1 (en) 2020-03-12
MY171620A (en) 2019-10-21
MX2020010780A (es) 2020-10-28
SG10202110501RA (en) 2021-11-29
CA2822219A1 (en) 2012-07-05
SG191392A1 (en) 2013-08-30
CN107019701A (zh) 2017-08-08
US20200093846A1 (en) 2020-03-26
MX2022011064A (es) 2022-10-07
US20120172319A1 (en) 2012-07-05
CN107019701B (zh) 2020-07-28
SG10201603856PA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
BR112013016905A2 (pt) métodos para diminuir incidência de enterocolite necrosante em bebês, crianças pequenas, ou crianças usando oligossacarídeos do leite humano
PH12017500874A1 (en) Human milk oligosaccharides for modulating inflammation
BR112013016606A2 (pt) processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios
MY174541A (en) Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
MY169326A (en) Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MX352040B (es) Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas.
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
BR112013016929A2 (pt) oligossacarídeos de leite humano para promover o crescimento de bactérias benéficas
MY196432A (en) Methods Of Using Human Milk Oligosaccharides For Improving Airway Respiratory Health
IN2015DN03862A (pt)
DK2498628T3 (da) Produkter til at formindske forekomsten af nekrotiserende enterocolitis, kolik og korttarmsyndrom hos et spædbarn, en tumling eller et barn
BR112013016914A2 (pt) combinação simbiótica de probióticos e oligossacarídeos do leite humano para promover o crescimento de microbiota benéfica
TR201904719T4 (tr) Diyet proteinlerine karşı toleransın oral indüksiyonu için sindirilemeyen oligosakkaridler.
WO2012129341A3 (en) Disease detection in plants
BR112014001472A2 (pt) galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
BR112013011088A2 (pt) composições de cereal em pó compreendendo microorganismos probióticos não replicantes
ECSP12012238A (es) Mead johnson nutrition company
WO2014179771A8 (en) Dosing combinations for reducing undesired humoral immune responses
WO2013033092A3 (en) Streptococcus suis pilus antigens
NZ626540A (en) Glutamine enriched nutritional composition for preterm infants
BR112014019486A8 (pt) Uso de um oligossacarídeo não digerível como um suplemento materno
PH12017500873A1 (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
IN2015KN00091A (pt)
NZ629711A (en) Anti-inflammatory compositions, methods and uses thereof
TR200801492A2 (tr) Özel hazırlanmış ballı kadayıf.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.